Vaxil Bio Ltd (VXL) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.042x

Based on the latest financial reports, Vaxil Bio Ltd (VXL) has a cash flow conversion efficiency ratio of -0.042x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-28.00K ≈ $-20.25K USD) by net assets (CA$667.00K ≈ $482.50K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Vaxil Bio Ltd defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Vaxil Bio Ltd - Cash Flow Conversion Efficiency Trend (2009–2024)

This chart illustrates how Vaxil Bio Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Vaxil Bio Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Vaxil Bio Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
ORUM KQ:475830	-0.045x
H&G High Conviction Ltd AU:HCF	-0.275x
LEGIBLE INC. F:D0T	N/A
Fashion Bel Air S.A PA:ALFBA	0.029x
Everyman Media Group plc LSE:EMAN	0.105x
Quintegra Solutions Limited NSE:QUINTEGRA	0.009x
Synectics plc LSE:SNX	0.110x
in Style Group PLC LSE:ITS	-0.054x

Annual Cash Flow Conversion Efficiency for Vaxil Bio Ltd (2009–2024)

The table below shows the annual cash flow conversion efficiency of Vaxil Bio Ltd from 2009 to 2024. For the full company profile with market capitalisation and key ratios, see Vaxil Bio Ltd (VXL) total market value.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CA$716.00K ≈ $517.94K	CA$-240.00K ≈ $-173.61K	-0.335x	+46.76%
2023-12-31	CA$891.00K ≈ $644.54K	CA$-561.00K ≈ $-405.82K	-0.630x	+2.55%
2022-12-31	CA$1.14 Million ≈ $821.77K	CA$-734.00K ≈ $-530.96K	-0.646x	-1.33%
2021-12-31	CA$1.70 Million ≈ $1.23 Million	CA$-1.08 Million ≈ $-784.15K	-0.638x	+53.52%
2020-12-31	CA$804.00K ≈ $581.60K	CA$-1.10 Million ≈ $-797.89K	-1.372x	-234.20%
2019-12-31	CA$-583.00K ≈ $-421.73K	CA$-596.00K ≈ $-431.14K	1.022x	+147.16%
2018-12-31	CA$435.00K ≈ $314.67K	CA$-943.00K ≈ $-682.15K	-2.168x	-205.47%
2017-12-31	CA$-487.00K ≈ $-352.29K	CA$-1.00 Million ≈ $-724.11K	2.055x	+190.01%
2016-12-31	CA$656.00K ≈ $474.54K	CA$-1.50 Million ≈ $-1.08 Million	-2.284x	-179.41%
2015-12-31	CA$-217.00K ≈ $-156.97K	CA$-624.00K ≈ $-451.39K	2.876x	+176.91%
2014-12-31	CA$34.48K ≈ $24.94K	CA$-128.91K ≈ $-93.25K	-3.739x	-83.25%
2013-12-31	CA$187.94K ≈ $135.95K	CA$-383.44K ≈ $-277.37K	-2.040x	+10.43%
2012-12-31	CA$72.15K ≈ $52.19K	CA$-164.34K ≈ $-118.88K	-2.278x	-31.42%
2011-12-31	CA$264.09K ≈ $191.04K	CA$-457.76K ≈ $-331.14K	-1.733x	-211.04%
2010-12-31	CA$682.06K ≈ $493.39K	CA$-380.10K ≈ $-274.96K	-0.557x	-98.24%
2009-12-31	CA$515.90K ≈ $373.20K	CA$-145.03K ≈ $-104.91K	-0.281x	--

About Vaxil Bio Ltd

V:VXL Canada Biotechnology

Market Cap

$455.81K

CA$630.10K CAD

Market Cap Rank

#30806 Global

#1654 in Canada

Share Price

CA$0.23

Change (1 day)

+0.00%

52-Week Range

CA$0.13 - CA$0.30

All Time High

CA$0.70